文献速递头颈外科咽喉与嗓音

局部晚期喉癌与下咽癌的诱导化疗:单中心经验

Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience.
PubMed 文献 · Head Neck · 2020-07-16

该单中心回顾性研究纳入104例局部晚期喉及下咽鳞癌患者,比较诱导化疗后放化疗与直接放化疗。

要点

  • 诱导化疗可显著改善局部晚期下咽癌的中位总生存与完全缓解率。
  • 诱导化疗未改善下咽癌的无病生存及局部区域或远处失败。
  • 喉癌患者中位总生存显著优于下咽癌患者。

核心结论

  • 诱导化疗显著提高放化疗后的完全缓解率,并改善局部晚期下咽癌而非喉癌的结局。

研究设计与样本

  • 单中心回顾性研究,纳入104例局部晚期喉及下咽鳞状细胞癌患者,接受诱导化疗或直接放化疗。

主要发现

  • 下咽癌组首次影像评估的完全缓解比例在诱导化疗后有显著差异。
  • 下咽癌组无病生存、局部区域失败或远处失败无显著差异。
  • 喉癌组总生存与无病生存无显著差异。
  • 喉癌患者中位总生存显著优于下咽癌患者。

临床怎么用

  • 对局部晚期下咽癌可考虑诱导化疗后放化疗以改善生存与完全缓解率。
  • 喉癌患者不应常规因生存获益而选择诱导化疗。

局限性

  • 回顾性单中心设计,诱导化疗组样本量较小(24例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of induction chemotherapy (IC) in locally-advanced head and neck squamous cell carcinoma (LAHNSCC) is unclear. METHODS: A retrospective study of 104 patients with LAHNSCC of the larynx and hypopharynx, treated with IC or up-front chemoradiotherapy (CRT). RESULTS: Eighty patients received CRT and 24 IC followed by CRT; median follow up was 51.33 months. IC significantly improved median overall survival (OS) in the hypopharyngeal cancer group (64.7 vs 21 months, P = .003); with significant difference in the proportion of complete response at first imaging assessment post definitive CRT; no significant difference in disease free survival (DFS), loco-regional or distant failure in the hypopharyngeal cancer group; or OS and DFS in the laryngeal cancer group. Patients with laryngeal cancer had significantly better median OS than those with hypopharyngeal cancer. CONCLUSIONS: IC significantly improved complete response rates after CRT, and improved outcomes for patients with locally advanced hypopharyngeal, not laryngeal, cancers.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Dagan O, Moore A, Nachalon Y, et al. Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience. Head Neck. 2020. PMID: 32671892. doi:10.1002/hed.26353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。